Answers are grounded in this paper and cite their sources.
Evaluative study synthesizes new compounds to assess cytotoxic effects in glioblastoma, suggesting potential therapeutic advancements.
2-Aryl-2-(3-indolyl)acetohydroxamic acids have emerged as promising antitumor agents; however, their poor pharmacokinetic profile remains a significant drawback. To address this limitation, we have synthesized a homolog of such acids—specifically 2-aryl-2-(3-indolyl)propionic acid (IC50 > 100 mM (U87)), along with several other derivatives: ethyl ester (IC50 > 100 mM (U87)), hydroxamate (IC50 21.2 ± 1.0 mM (U87)) and hydrazide (IC50 > 100 mM (U87)). The cytotoxicity of these compounds against glioblastoma cell lines was evaluated and compared to that of the parent acetohydroxamic acid derivatives.
No takes yet. Share an insight, caveat, or question.
Аксенов et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: